Influence of Androgen Deprivation Therapy on the Development of Sarcopenia in Patients with Prostate Cancer: A Systematic Review-Reference-Cited by-同舟云学术

Influence of Androgen Deprivation Therapy on the Development of Sarcopenia in Patients with Prostate Cancer: A Systematic Review

Published:2024-02-26 Issue:5 Volume:16 Page:656
ISSN:2072-6643
Container-title:Nutrients
language:en
Short-container-title:Nutrients

Author:

Stelmach-Mardas Marta¹^ORCID,Warchoł Wojciech²,Garczyk Aleksandra¹,Warchoł Emilia¹,Korczak Jolanta³,Litwiniuk Maria⁴,Brajer-Luftmann Beata⁵,Mardas Marcin⁶

Affiliation:

1. Department of Obesity Treatment, Metabolic Disorders and Clinical Dietetics, Poznan University of Medical Sciences, 60-569 Poznan, Poland

2. Department of Ophthalmology and Optometry, Poznan University of Medical Sciences, 60-806 Poznan, Poland

3. Department of Chemotherapy, The Greater Poland Cancer Center, 61-866 Poznan, Poland

4. Department of Cancer Pathology and Prevention, Poznan University of Medical Sciences, 61-866 Poznan, Poland

5. Department of Pulmonology, Allergology and Pulmonary Oncology, Poznan University of Medical Sciences, 60-569 Poznan, Poland

6. Department of Gynecological Oncology, Institute of Oncology, Poznan University of Medical Sciences, 60-569 Poznan, Poland

Abstract

The changes in body composition during androgen deprivation therapy (ADT) in patients suffering from prostate cancer (PCa) are recognized by professionals more often as biomarker for effective treatment. The aim of this study was to investigate the impact of ADT on the sarcopenia development in PCa. The following databases were used: PubMed, Embase, Web of Science and Scopus databases. Out of 2183 studies, 7 were included in this review. The fixed-effect model was used in the meta-analysis. A significant increase in SATI (Subcutaneous Adipose Tissue Index) of 0.32 (95% CI: 0.13–0.51) p = 0.001, decrease in SMI (Skeletal Muscle Index) of −0.38 (95% CI: −0.57 to −0.19) p < 0.0001, and SMD (Skeletal Muscle Density) of −0.46 (95% CI: −0.69 to −0.24) p < 0.0001 were observed. No statistical association was visible between ADT and changes in BMI (Body Mass Index), 0.05 (95% CI: −0.18–0.28), p = 0.686, and VATI (Visceral Adipose Tissue Index): 0.17 (95% CI: −0.02 to 0.37), p = 0.074. In conclusion, the ADT significantly contributes to the body composition changes and sarcopenia development.

Publisher

MDPI AG

Link

https://www.mdpi.com/2072-6643/16/5/656/pdf

Reference41 articles.

1. Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone-sensitive prostate cancer;Sathianathen;Cochrane Database Syst. Rev.,2020

2. Associations of Fat and Muscle Mass with Overall Survival in Men with Prostate Cancer: A Systematic Review with Meta-Analysis;Lopez;Prostate Cancer Prostatic Dis.,2022

3. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries;Sung;CA A Cancer J. Clin.,2021

4. Supervised Exercise Therapy Compared with No Exercise Therapy to Reverse Debilitating Effects of Androgen Deprivation Therapy in Patients with Prostate Cancer: A Systematic Review and Meta-Analysis;Ussing;Prostate Cancer Prostatic Dis.,2022

5. Shao, W., Zhang, H., Qi, H., and Zhang, Y. (2022). The Effects of Exercise on Body Composition of Prostate Cancer Patients Receiving Androgen Deprivation Therapy: An Update Systematic Review and Meta-Analysis. PLoS ONE, 17.